The study was carried to determine the analgesic efficacy of greater occipital nerve block in patients of migraine. It was a randomised controlled which took place from april 2022 - october 2022. Fifty patients suffering from migraine were included in the study. Patients in Group G were given greater occipital nerve block (GONB) with lignocaine and dexamethasone under ultrasound guidance while those in Group S were given saline 0.9% as placebo. Pain score using Numeric Rating Scale and number of headache days was assessed at four,eight and twelve weeks after the procedure as a primary outcome. Total headache days were recorded as a secondary outcome.

Inclusion Criteria:

• Patients between 18 to 60 years
• diagnosed case of migraine

Exclusion Criteria:

• Patients with known allergies to local anaesthetics
• pregnancy
• history of cranial or cervical surgery
• head injury
• headaches secondary to medication overuse
• patients with uncontrolled systemic disease like blood pressure, diabetes mellitus
• hypo or hyperthyroidism
• patient who had already received GONB or botulinum toxin type A therapy within last 6 months
• major psychiatric disorder
• history of chronic pain syndromes